Logo image of ADAG

ADAGENE INC-ADR (ADAG) Stock Fundamental Analysis

NASDAQ:ADAG - US0053291078 - ADR

2.13 USD
-0.09 (-4.05%)
Last: 8/29/2025, 4:30:00 PM
Fundamental Rating

2

ADAG gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 547 industry peers in the Biotechnology industry. ADAG may be in some trouble as it scores bad on both profitability and health. ADAG does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ADAG has reported negative net income.
ADAG had a negative operating cash flow in the past year.
ADAG had negative earnings in each of the past 5 years.
In the past 5 years ADAG always reported negative operating cash flow.
ADAG Yearly Net Income VS EBIT VS OCF VS FCFADAG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

ADAG has a better Return On Assets (-37.44%) than 60.69% of its industry peers.
ADAG has a Return On Equity of -66.16%. This is comparable to the rest of the industry: ADAG outperforms 58.68% of its industry peers.
Industry RankSector Rank
ROA -37.44%
ROE -66.16%
ROIC N/A
ROA(3y)-35.43%
ROA(5y)-39.1%
ROE(3y)-63.08%
ROE(5y)-60.3%
ROIC(3y)N/A
ROIC(5y)N/A
ADAG Yearly ROA, ROE, ROICADAG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ADAG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADAG Yearly Profit, Operating, Gross MarginsADAG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K

More info and screens

3

2. Health

2.1 Basic Checks

ADAG does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ADAG has more shares outstanding
Compared to 5 years ago, ADAG has more shares outstanding
Compared to 1 year ago, ADAG has a worse debt to assets ratio.
ADAG Yearly Shares OutstandingADAG Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ADAG Yearly Total Debt VS Total AssetsADAG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -3.92, we must say that ADAG is in the distress zone and has some risk of bankruptcy.
ADAG's Altman-Z score of -3.92 is in line compared to the rest of the industry. ADAG outperforms 44.61% of its industry peers.
A Debt/Equity ratio of 0.10 indicates that ADAG is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.10, ADAG is not doing good in the industry: 64.17% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z -3.92
ROIC/WACCN/A
WACC8.2%
ADAG Yearly LT Debt VS Equity VS FCFADAG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

ADAG has a Current Ratio of 2.30. This indicates that ADAG is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ADAG (2.30) is worse than 70.93% of its industry peers.
ADAG has a Quick Ratio of 2.30. This indicates that ADAG is financially healthy and has no problem in meeting its short term obligations.
ADAG's Quick ratio of 2.30 is on the low side compared to the rest of the industry. ADAG is outperformed by 68.74% of its industry peers.
Industry RankSector Rank
Current Ratio 2.3
Quick Ratio 2.3
ADAG Yearly Current Assets VS Current LiabilitesADAG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

3

3. Growth

3.1 Past

ADAG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -71.88%.
Looking at the last year, ADAG shows a very negative growth in Revenue. The Revenue has decreased by -99.43% in the last year.
ADAG shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -26.47% yearly.
EPS 1Y (TTM)-71.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.81%
Revenue 1Y (TTM)-99.43%
Revenue growth 3Y-78.36%
Revenue growth 5Y-26.47%
Sales Q2Q%-87.35%

3.2 Future

The Earnings Per Share is expected to grow by 4.90% on average over the next years.
The Revenue is expected to grow by 60.72% on average over the next years. This is a very strong growth
EPS Next Y-1.9%
EPS Next 2Y-1.2%
EPS Next 3Y-5.18%
EPS Next 5Y4.9%
Revenue Next Year8.17%
Revenue Next 2Y18.55%
Revenue Next 3Y-0.8%
Revenue Next 5Y60.72%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ADAG Yearly Revenue VS EstimatesADAG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
ADAG Yearly EPS VS EstimatesADAG Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ADAG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADAG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADAG Price Earnings VS Forward Price EarningsADAG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADAG Per share dataADAG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

A cheap valuation may be justified as ADAG's earnings are expected to decrease with -5.18% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.2%
EPS Next 3Y-5.18%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ADAG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADAGENE INC-ADR

NASDAQ:ADAG (8/29/2025, 4:30:00 PM)

2.13

-0.09 (-4.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)N/A N/A
Inst Owners25.27%
Inst Owner Change-5.54%
Ins Owners2.77%
Ins Owner ChangeN/A
Market Cap100.34M
Analysts78
Price Target9.84 (361.97%)
Short Float %0.17%
Short Ratio0.59
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)67.7%
PT rev (3m)-4.56%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)3.36%
EPS NY rev (3m)3.36%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)50.09%
Revenue NY rev (3m)50.09%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 972.32
P/FCF N/A
P/OCF N/A
P/B 1.99
P/tB 1.99
EV/EBITDA N/A
EPS(TTM)-0.72
EYN/A
EPS(NY)-0.68
Fwd EYN/A
FCF(TTM)-0.63
FCFYN/A
OCF(TTM)-0.63
OCFYN/A
SpS0
BVpS1.07
TBVpS1.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -37.44%
ROE -66.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-35.43%
ROA(5y)-39.1%
ROE(3y)-63.08%
ROE(5y)-60.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.65%
Cap/Sales 32.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.3
Quick Ratio 2.3
Altman-Z -3.92
F-Score2
WACC8.2%
ROIC/WACCN/A
Cap/Depr(3y)24.44%
Cap/Depr(5y)80.95%
Cap/Sales(3y)13.48%
Cap/Sales(5y)39.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-71.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.81%
EPS Next Y-1.9%
EPS Next 2Y-1.2%
EPS Next 3Y-5.18%
EPS Next 5Y4.9%
Revenue 1Y (TTM)-99.43%
Revenue growth 3Y-78.36%
Revenue growth 5Y-26.47%
Sales Q2Q%-87.35%
Revenue Next Year8.17%
Revenue Next 2Y18.55%
Revenue Next 3Y-0.8%
Revenue Next 5Y60.72%
EBIT growth 1Y-51.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year10.42%
EBIT Next 3Y-18.21%
EBIT Next 5YN/A
FCF growth 1Y-4.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4.38%
OCF growth 3YN/A
OCF growth 5YN/A